Skip to main content
Explore URMC

URMC Logo

Jean M. Bidlack, Ph.D.

Contact Information

Phone Numbers

Office: (585) 275-5600

Fax: (585) 273-2652

Biography

Research

Discovery of Samidorphan, a medication currently in multiple Phase 2 and Phase 3 clinical trials:

In collaboration with Dr. Mark P. Wentland at Rensselaer Polytechnic Institute, the main goal of our research is to design, synthesize and characterize oral, long-acting modulators of opioid G protein-coupled receptors (GPCRs) as medications to treat cocaine abuse and other central nervous system disorders in humans. A common structural feature of the large majority of opioids is a phenolic-OH group (see prototypic opioid structure below) that plays a crucial role in molecular recognition via H-bonding to a histidine residue of an opioid GPCR. For many opioids, however, this OH group is responsible for poor oral bioavailability and/or short half-life via O-glucuronidation. In 2001, we published the first report that a carboxamide group (CONH2) was an effective replacement for this prototypic phenolic-OH group of opioids. In addition to high affinity binding to opioid GPCRs, certain carboxamido-substituted opioids have much improved pharmacokinetic properties (relative to their phenolic-OH counterparts) as a consequence of high metabolic stability.

Since 2001, our research group has focused on capitalizing on this discovery to achieve our main goal. Our first-generation opioid modulator in this series was 8-carboxamidocyclazocine (8-CAC) and a next generation agent is samidorphan (formerly referred to as ALKS 33). 8-CAC produced analgesia in mice for 16 hours in comparison to morphine which produces analgesia for less than 2 hours. Our publications describing these discoveries as well as a wealth of structure-activity relationship data are catalogued in the PubMed link found below.

In September 2006, Rensselaer signed a license agreement granting Alkermes Inc. - a biotechnology company now based in Ireland - exclusive rights to a library of opioid compounds discovered by our team. The Bidlack lab continues to work with Alkermes to discover new opioids that may be pharmacotherapeutics. Alkermes recently announced the initiation of multiple phase 3 clinical studies of ALKS 5461 (samidorphan in combination with buprenorphine) for treatment of patients with major depressive disorder. The U.S. Food and Drug Administration (FDA) has granted Fast Track status for ALKS 5461. Alkermes also announced the initiation of multiple phase 2 clinical studies of ALKS 3831, a novel oral atypical antipsychotic drug candidate designed to be a broad spectrum treatment for schizophrenia. ALKS 3831 is composed of samidorphan in combination with the established antipsychotic drug, olanzapine. See the following press releases from Alkermes for details:

Alkermes Announces Initiation of FORWARD-3 and FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461 for Treatment of Major Depressive Disorder

Alkermes Announces Initiation of ALKS 5461 Pivotal Clinical Program for Treatment of Major Depressive Disorder

Alkermes Receives Fast Track Designation for ALKS 5461 for Major Depressive Disorder

Alkermes Announces Initiation of Second Phase 2 Clinical Study of ALKS 3831, a Novel Broad-Spectrum Oral Antipsychotic

Alkermes Announces Initiation of Phase 2 Clinical Study of ALKS 3831, Designed to Be a Broad Spectrum Oral Antipsychotic for the Treatment of Schizophrenia

Credentials

Faculty Appointments

Education

1979
PhD | Univ Rochester Sch Med/Dent
Biophysics

1977
MS | Univ Rochester Sch Med/Dent
Biophysics

1975
BA | Skidmore College
Biology - Chemistry

Awards

2010 - Present
College of CSR Reviewers
Sponsor: National Institutes of Health

2007
Excellence in Research Award
Sponsor: University of Rochester

2007
University Dean's Award for Meritorious Service in Ph.D. Defenses
Sponsor: University of Rochester

2005
Distinguished Service Award
Sponsor: Society on NeuroImmune Pharmacology

2004
Periclean Alumna Scholar Award
Sponsor: Skidmore College

2001
The Alumni Award for Excellence in Graduate Education
Sponsor: University of Rochester

1998 - 2008
NIH Senior Scientist Award
Sponsor: National Institute of Health

1995
Wallace O. Fenn Mentor Award
Sponsor: University of Rochester

1975
Periclean Scholar Award
Sponsor: Skidmore College

VIEW ALL expand_more

Patents

Title: Treatment of Cocaine Abuse Using N-Substituted Derivatives of Morphinan
U.S. Serial #: 11/029,247
Filed: Jan 04, 2005
Invented By: JeanBidlack, Xia-HuiGu, JohnNeumeyer

Title: N-Substituted Derivatives of Morphinan and Uses Thereof
U.S. Serial #: 10/222,736
Filed: Aug 15, 2002
Invented By: JeanBidlack, Xia-HuiGu, JohnNeumeyer

Publications

Journal Articles

8/13/2015
Lefever M, Li Y, Anglin B, Muthu D, Giuvelis D, Lowery JJ, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. "Structural Requirements for CNS Active Opioid Glycopeptides." Journal of medicinal chemistry.. 2015 Aug 13; 58(15):5728-41. Epub 2015 Jul 23.

3/27/2014
Li Y, St Louis L, Knapp BI, Muthu D, Anglin B, Giuvelis D, Bidlack JM, Bilsky EJ, Polt R. "Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to ?-endorphin?" Journal of medicinal chemistry.. 2014 Mar 27; 57(6):2237-46. Epub 2014 Mar 07.

2/19/2014
Sromek AW, Provencher BA, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL. "Preliminary pharmacological evaluation of enantiomeric morphinans." ACS chemical neuroscience. 2014 Feb 19; 5(2):93-9. Epub 2014 Jan 08.

Books & Chapters

2009
Chapter Title: The Chemistry and Pharmacology of Mu Opioid Antagonists
Book Title: Opiate Receptors and Antagonists: From Bench to Clinic
Author List: Bidlack, J.M., and Mathews, J.L.
Edited By: R. Dean, S.S. Negus, and E. Bilsky
Published By: Humana Press2009 in Totowa, NJ

2007
Chapter Title: Review of Carleton K. Erickson. The Science of Addiction: From Neurobiology to Treatment.
Book Title: Phi Kappa Phi Forum
Author List: Bidlack, JM
Published By: W.W. Norton & Company2007 in New York

VIEW ALL PUBLICATIONS